Cingulate Inc. (CING)
NasdaqCM: CING
· 即時價格 · USD
5.22
+0.07 (1.36%)
收盤價： Sep 04, 2026, 12:04 PM
股價、關鍵數字和最新消息，都在這一頁。
Cingulate Inc.（CING）股價、分析與資料
1.36% (1D)
| 買價 | 3.68 |
| 市值 | 73.8M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -28.8M |
| -0.91 | |
| -3.56 | |
| n/a | |
| -5.77 | |
| P/B (ttm) | 3.01 |
| P/S (ttm) | 0.00 |
| 財報日期 | n/a |
| 賣價 | 6.77 |
| 成交量 | 81,955 |
| 20 日平均成交量 | 236,276 |
| 開盤價 | 5.19 |
| 前收盤價 | 5.15 |
| 當日區間 | 5.06 - 5.27 |
| 52 週範圍 | 3.16 - 11.89 |
| 分析師 | 強<br>購買 |
| 目標價 | 20 (283.14%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a f...
完整的公司簡介財報驚奇
Cingulate 已於 Aug 13, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.45 超出預期 0.11, 年增 58.72% 成長.
